2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Essential Thrombocytosis: new trials by email Literature Review of Essential Thrombocytosis trials Research Report on Essential Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
| Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis lestaurtinib - Polycythemia Vera, Essential Thrombocytosis | Phase 2 | Completed | Cephalon | 39 | 2007-12-01 | 2015-10-08 |
Thrombocythemia, Essential (2) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Polycythemia Vera (1) · Precancerous Conditions (1) · Preleukemia (1) · Primary Myelofibrosis (1)
Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Thrombocytosis (2) · Bone Marrow Diseases (1) · Bone Marrow Neoplasms (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Site (1)
CPI-0610 (1) · lestaurtinib (1) · ruxolitinib (1)
Cephalon (1) · Constellation Pharmaceuticals (1)
United States (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
PMID 24903629, PMID 36881782, PMID 37530627, PMID 38259250
2018 (1)